Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma

GlobeNewswire April 18, 2018

Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018

GlobeNewswire April 13, 2018

Calithera to Present at Needham & Company 17th Annual Healthcare Conference

GlobeNewswire March 23, 2018

Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights

GlobeNewswire March 8, 2018

Calithera Biosciences, Inc. to Host Earnings Call

Accesswire March 8, 2018

Calithera to Present at Cowen & Company 38th Annual Health Care Conference

GlobeNewswire March 6, 2018

Calithera Biosciences to Report Fourth Quarter 2017 Financial Results on Thursday, March 8, 2018

GlobeNewswire March 2, 2018

Calithera to Participate in Leerink Partners 7th Annual Global Healthcare Conference

GlobeNewswire February 9, 2018

Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium

GlobeNewswire February 5, 2018

Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium

GlobeNewswire December 5, 2017

Report: Exploring Fundamental Drivers Behind Parsley Energy, Analog Devices, Exxon Mobil, Calithera Biosciences, Monster Beverage, and Marathon Petroleum — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 28, 2017

Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting

GlobeNewswire November 7, 2017

Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights

GlobeNewswire November 2, 2017

Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda

GlobeNewswire October 19, 2017

Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel

GlobeNewswire October 3, 2017

Calithera Biosciences Appoints Blake Wise to Board of Directors

GlobeNewswire September 21, 2017

Stocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and Cytokinetics

PR Newswire September 21, 2017

Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable

GlobeNewswire September 20, 2017

Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

GlobeNewswire September 19, 2017

Calithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference

GlobeNewswire August 30, 2017